Onset of Pyoderma Gangrenosum in Patients on Biologic Therapies: A Systematic Review

CONCLUSIONS Further investigations are warranted to determine whether PG onset is associated with underlying comorbidities, the use of biologic agents, or a synergistic effect. Nevertheless, PG may develop in patients on rituximab or TNF-α inhibitors, suggesting the need to monitor and treat such adverse effects.
Source: Advances in Skin and Wound Care - Category: Dermatology Tags: LITERATURE REVIEWS Source Type: research